
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.084
vdae090.084
Final Category: Novel Targets in CNS Metastases (Non-Immunologic)
AcademicSubjects/MED00300
AcademicSubjects/MED00310
NVTG-10 CLINICAL AND RADIOLOGICAL OUTCOMES OF ORBITAL METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY: A SINGLE INSTITUTION RETROSPECTIVE SERIES
Zamarud Aroosa Stanford University, School of Medicine, Palo Alto, USA

Hori Yusuke S Stanford University, School of Medicine, Palo Alto, USA

Kattaa Ahed H Stanford University, School of Medicine, Palo Alto, USA

Persad Amit R Stanford University, School of Medicine, Palo Alto, USA

Tayag Armine Stanford University, School of Medicine, Palo Alto, USA

Usttrzinsky Louisa Stanford University, School of Medicine, Palo Alto, USA

Emrich Sara Coleman Stanford University, School of Medicine, Palo Alto, USA

Soltys Scott G Stanford University, School of Medicine, Palo Alto, USA

Hancock Steven L Stanford University, School of Medicine, Palo Alto, USA

Park David J Stanford University, School of Medicine, Palo Alto, USA

Chang Steven D Stanford University, School of Medicine, Palo Alto, USA

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i25i26
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

INTRODUCTION

Orbital metastases (OM) are a rare complication of cancer that can result in visual impairment. Treatment options include surgery and radiotherapy, however, the optimal treatment for OM is unclear. The current evidence for stereotactic radiosurgery (SRS) is limited. We aim to report the efficacy and safety of SRS in patients with OM.

METHODS

The clinical and radiological outcomes of patients with OM treated with SRS between April 2006 and November 2023 were retrospectively reviewed. SRS was utilized to treat all the tumors. The post-treatment tumors were radiologically categorized to stable disease (SD), partial response (PS), and complete response per RECIST criteria.

RESULTS

We included 15 patients with 17 OM lesions in our study; 9 (60%) of whom were females, and their median age was 62 years (range: 21-82 years). The median overall survival was 6.5 months (range: 2-62 months). All these patients were treated with standalone CK SRS. The most common fractionation schedules were 24 Gy in 3 fractions (n=4). The median diameter of the lesions was 21 mm (range: 11-72 mm). The median volume treated was 2.6 cm3 (range: 0.3-78.8). At the last follow-up, 13 tumors (76.5%) showed SD, 2 tumors (11.8%) showed PR, 2 tumors (11.8%) showed CR, and no tumor (0%) showed PD. The lesions were followed for a median of 7 months (range: 2-62 months). The local control rates were 100% at 6-month and 12-month. No immediate or long-term radiation-induced necrosis was reported.

CONCLUSION

This is the largest series on OM treated with CK SRS with substantial follow-up data. Our study shows an excellent local tumor control with no immediate and long-term radiation induced necrosis.
==== Body
pmc
